Similar to selective modulators of other nuclearreceptors such as the estrogen receptor (SERMs), LG101506binding to RXR selectively maintains the desirable characteristiceffects of rexinoids while minimizing the undesirable effects.These recent findings suggest that, with continued research efforts,RXR-specific ligands with improved pharmacological profiles mayeventually be available as additional treatment options for thecurrent epidemic of obesity, insulin resistance, type 2 diabetes,and all of the associated metabolic sequelae. The gene discussed is ESR1; the disease is obesity disorder.